Brain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects
Anti-obesity drugs in the amphetamine (AMPH) class act in the brain to reduce appetite and increase locomotion. They are also characterized by adverse cardiovascular effects with origin that, despite absence of any in vivo evidence, is attributed to a direct sympathomimetic action in the heart. Here...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2020
|
| _version_ | 1797102861976338432 |
|---|---|
| author | Mahú, I Barateiro, A Rial-Pensado, E Domingos, A |
| author_facet | Mahú, I Barateiro, A Rial-Pensado, E Domingos, A |
| author_sort | Mahú, I |
| collection | OXFORD |
| description | Anti-obesity drugs in the amphetamine (AMPH) class act in the brain to reduce appetite and increase locomotion. They are also characterized by adverse cardiovascular effects with origin that, despite absence of any in vivo evidence, is attributed to a direct sympathomimetic action in the heart. Here, we show that the cardiac side effects of AMPH originate from the brain and can be circumvented by PEGylation (PEGyAMPH) to exclude its central action. PEGyAMPH does not enter the brain and facilitates SNS activity via theβ2-adrenoceptor, protecting mice against obesity by increasing lipolysis and thermogenesis, coupled to higher heat dissipation, which acts as an energy sink to increase energy expenditure without altering food intake or locomotor activity. Thus, we provide proof-of-principle for a novel class of exclusively peripheral anti-obesity sympathofacilitators that are devoid of any cardiovascular and brain-related side effects.
|
| first_indexed | 2024-03-07T06:11:49Z |
| format | Journal article |
| id | oxford-uuid:efc49931-dcb8-4980-881d-8b691850a77b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:11:49Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:efc49931-dcb8-4980-881d-8b691850a77b2022-03-27T11:42:46ZBrain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effectsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:efc49931-dcb8-4980-881d-8b691850a77bEnglishSymplectic ElementsElsevier2020Mahú, IBarateiro, ARial-Pensado, EDomingos, AAnti-obesity drugs in the amphetamine (AMPH) class act in the brain to reduce appetite and increase locomotion. They are also characterized by adverse cardiovascular effects with origin that, despite absence of any in vivo evidence, is attributed to a direct sympathomimetic action in the heart. Here, we show that the cardiac side effects of AMPH originate from the brain and can be circumvented by PEGylation (PEGyAMPH) to exclude its central action. PEGyAMPH does not enter the brain and facilitates SNS activity via theβ2-adrenoceptor, protecting mice against obesity by increasing lipolysis and thermogenesis, coupled to higher heat dissipation, which acts as an energy sink to increase energy expenditure without altering food intake or locomotor activity. Thus, we provide proof-of-principle for a novel class of exclusively peripheral anti-obesity sympathofacilitators that are devoid of any cardiovascular and brain-related side effects. |
| spellingShingle | Mahú, I Barateiro, A Rial-Pensado, E Domingos, A Brain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects |
| title | Brain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects |
| title_full | Brain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects |
| title_fullStr | Brain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects |
| title_full_unstemmed | Brain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects |
| title_short | Brain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects |
| title_sort | brain sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects |
| work_keys_str_mv | AT mahui brainsparingsympathofacilitatorsmitigateobesitywithoutadversecardiovasculareffects AT barateiroa brainsparingsympathofacilitatorsmitigateobesitywithoutadversecardiovasculareffects AT rialpensadoe brainsparingsympathofacilitatorsmitigateobesitywithoutadversecardiovasculareffects AT domingosa brainsparingsympathofacilitatorsmitigateobesitywithoutadversecardiovasculareffects |